The Clarity Pharmaceuticals Ltd (ASX: CU6) share price is in focus today after the company reported a 68% jump in revenue to $8 million, alongside a net loss of $107.2 million for the year ended 30 June 2026.
What did Clarity Pharmaceuticals report?
- Revenue increased 68% to $8.0 million
- Net loss after tax widened to $107.2 million (up 67%)
- Research and development spend rose to $91.1 million
- Liquid assets grew to $178.3 million at year end
- No dividend declared for FY26
- Net tangible assets per share up to 49.9 cents (from 28.1 cents)
What else do investors need to know?
Clarity raised $203 million in fresh capital through a placement at the end of July 2025, strengthening its cash reserves for future clinical trials and commercialisation. The company received a $9.8 million R&D tax incentive refund, highlighting its ongoing investment in Australian radiopharmaceutical research.
The year was marked by significant clinical progress, with flagship prostate and neuroendocrine tumour imaging and therapy candidates advancing through multiple phase II and phase III trials. Manufacturing and supply agreements were expanded to support the anticipated launch of key products.
What did Clarity Pharmaceuticals management say?
Executive Chair Dr Alan Taylor said:
Our strong progress across clinical, regulatory, and manufacturing activities this year lays the foundation for our transition from developer to commercial stage. We remain focused on bringing innovative diagnostic and therapeutic radiopharmaceuticals to patients globally.
What’s next for Clarity Pharmaceuticals?
Clarity is prioritising late-stage clinical trials and regulatory submissions in the US for its core copper-based SAR technology platform. The company will also focus on building its commercial infrastructure, supported by expanded manufacturing capabilities and new executive appointments.
Looking ahead, Clarity remains well funded and plans to progress new studies targeting unmet needs in cancer care, while preparing for product launches in the US and other key markets.
Clarity Pharmaceuticals share price snapshot
Over the past 12 months, Clarity Pharmaceuticals shares have declined 33%, trailing the All Ordinaries Index (ASX: XAO), which is flat over the same period.
The post Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses appeared first on The Motley Fool Australia.
Should you invest $1,000 in Clarity Pharmaceuticals right now?
Before you buy Clarity Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Clarity Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- This ASX biotech is tipped to more than double in value
- Clarity Pharmaceuticals reports clinical trial milestones
- Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose
- Clarity Pharmaceuticals reports clinical progress in June 2026 quarter
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.